Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06757348 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fatty Liver and Pancreatic Steatosis

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 6, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Mar 1, 2025 to Sep 1, 2025v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients. Participants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).
Trial Details
NCT Number NCT06757348
Lead Sponsor Maria Marta Piskorz
Conditions
(from sponsor)		 Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic Steatosis
Related terms Exocrine Pancreatic Insufficiency, Fatty Liver, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov